ABBVIE INC

AbbVie’s latest conference plans and strong market performance spotlight its immunology R&D and growing opportunities in the autoimmune uveitis market.

AbbVie’s latest growth strategy: $8B bond‑backed acquisition, Wells Fargo’s bullish HS target, and new oncology pipeline, all driving a $442B valuation.

AbbVie’s bold moves—boosting science talent, securing Humira’s future, and acquiring Apogee—show a biotech powerhouse turning strategy into shareholder value.

AbbVie’s July 2026 ex‑dividend and Skyrizi‑driven $300 target show a resilient dividend strategy amid a brief price dip, yet drug‑pricing policy shifts still shape future gains.

AbbVie’s Apogee deal shifts focus from Humira to a diversified pipeline, targeting immunology, oncology, and neurology breakthroughs.

AbbVie’s EPCORE DLBCL‑4 trial shows a 60% reduction in progression risk with epcoritamab + lenalidomide, boosting investor confidence and expanding its oncology and dermatology portfolio amid regulatory wins and global collaborations.

AbbVie’s $10.9B acquisition of Apogee and FDA approval of Skyrizi for pediatric psoriasis signal a robust pipeline expansion and new revenue streams amid biosimilar competition.

AbbVie’s steady dividend, Crohn’s disease expansion plans, and $1.4B manufacturing investment reveal a robust strategy that balances shareholder returns with future growth opportunities.

AbbVie’s stock faces a bearish trend, but strong dividends, a 10% sales growth, and a $650 M partnership with RemeGen hint at resilience – can investors ride the dip or risk a slide?

AbbVie partners with MLB to boost its oncology campaign, using sports reach to spread cancer awareness and potentially lift its undervalued stock.